A feasibility study of neoadjuvant docetaxel+cisplatin+fluorouracil (DCF) with pegfilgrastim on day3 for patients with esophageal cancer

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2020
This article has no abstract
Epistemonikos ID: d912b2b21de90381bd08947a1a3adc12a66a9baa
First added on: Apr 11, 2025